Biogen Inc. (FRA:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 17.31B |
| Revenue (ttm) | 8.51B |
| Net Income (ttm) | 1.30B |
| Shares Out | n/a |
| EPS (ttm) | 8.90 |
| PE Ratio | 13.28 |
| Forward PE | 9.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30 |
| Average Volume | 107 |
| Open | 117.05 |
| Previous Close | 117.05 |
| Day's Range | 117.05 - 117.05 |
| 52-Week Range | 99.82 - 176.70 |
| Beta | n/a |
| RSI | 42.46 |
| Earnings Date | Oct 30, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massac...
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Biogen Inc. (NASDAQ:BIIB) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDT Company Participants Priya Singhal - Executive VP & Head of Development Conference Call Par...
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massac...
US FDA declines to approve higher-dose of Biogen's genetic disorder drug
The U.S. Food and Drug Administration has declined to approve a higher dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, dealing a setback to the compa...
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company...
A Look Into Biogen Inc's Price Over Earnings
Looking into the current session, Biogen Inc. (NASDAQ: BIIB) shares are trading at $145.60, after a 0.50% spike. Moreover, over the past month, the stock increased by 4.28% , but in the past year, fe...
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M
Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M
December 19th Options Now Available For Biogen (BIIB)
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the December 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...
Biogen (BIIB) to Acquire Alcyone Therapeutics for Innovative Drug Delivery System
Biogen (BIIB) to Acquire Alcyone Therapeutics for Innovative Drug Delivery System
Biogen to buy Massachusetts-based Alcyone Therapeutics
Biogen To Acquire Alcyone Therapeutics
(RTTNews) - Biogen Inc. (BIIB), a biotechnology company, on Thursday announced that it has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics for an upfront cash p...
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As pa...
Biogen (BIIB) Gains EU Approval for Post-Partum Depression Treatment
Biogen (BIIB) Gains EU Approval for Post-Partum Depression Treatment
Biogen (BIIB) Receives E.U. Approval for ZURZUVAE in Treating Postpartum Depression
Biogen (BIIB) Receives E.U. Approval for ZURZUVAE in Treating Postpartum Depression
Biogen gets EU nod for Zurzuvae to treat post-partum depression
Biogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum dep...
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat pos...
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News
Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance
Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector
Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector
Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...